EUVIMEDEUVIMED entdecken
Crossref

Are COMPASS Candidates Among Internal Medicine Patients? Insights from the Internal Medicine Clinic

Rosado Julião, Sofia, Rodrigues Lopes, Andreia, Palácios, Diana, Lemos Sargento, Dora, Teresa Fonseca, Alves, Mariana

Medicina Interna · 06.07.2023

DOI: 10.24950/rspmi.2176 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicina Interna, erschienen am 06.07.2023. Verfasst von Rosado Julião und 10 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

We sought to evaluate if internal medicine outpatients are candidates to COMPASS trial strategy (low dose rivaroxaban twice a day plus daily acetylsalicylic acid), to detail the inclusion and exclusion criteria of COMPASS trial presented by internal medicine patients and to evaluate the frequency of patients already under the strategy.

Methods

Observational, retrospective, and transversal study in an internal medicine department of a tertiary university hospital. During a one-month period, we consulted all electronic medical records of internal medicine appointments to assess which patients presented inclusion and exclusion criteria of the COMPASS trial.

Results

Of 228 patients, 40 (17.5%) met inclusion criteria for COMPASS trial. Twelve (30.0%) had coronary artery disease, 21 (52.5%) had peripheral artery disease, and 6 (1.5%) had both. One patient was already on the COMPASS trial strategy. Of those who met inclusion criteria, 70.0% (n = 28) presented at least one exclusion criteria. The most frequent was the use of oral anticoagulation (mostly due to atrial fibrillation), followed by the users of non-acetylsalicylic acid antiplatelet therapy.

Conclusion

The number of internal medicine patients who are eligible to benefit from the COMPASS strategy is relevant. Internal medicine physicians must be aware of inclusion and exclusion criteria of this new prevention strategy to promptly apply it in clinical practice.

Schlagwörter

COMPASS trialrivaroxabanaspirindual antiplatelet therapysecondary preventioncoronary artery diseaseperipheral arterial diseaseatrial fibrillationoral anticoagulationantiplatelet therapy

Zitieren

APA

Julião, R., Sofia, Lopes, R., Andreia, Palácios, Diana, Sargento, L., Dora, Fonseca, T., Alves, & Mariana (2023). Are COMPASS Candidates Among Internal Medicine Patients? Insights from the Internal Medicine Clinic. Medicina Interna. https://doi.org/10.24950/rspmi.2176

Vancouver

Julião R, Sofia, Lopes R, Andreia, Palácios, Diana, et al. Are COMPASS Candidates Among Internal Medicine Patients? Insights from the Internal Medicine Clinic. Medicina Interna. 2023. doi:10.24950/rspmi.2176

BibTeX
@article{Julio2023,
  author = {Julião, Rosado and Sofia and Lopes, Rodrigues and Andreia and Palácios and Diana and Sargento, Lemos and Dora and Fonseca, Teresa and Alves and Mariana},
  title = {Are COMPASS Candidates Among Internal Medicine Patients? Insights from the Internal Medicine Clinic},
  journal = {Medicina Interna},
  year = {2023},
  doi = {10.24950/rspmi.2176}
}
Kostenlos starten →